solid tumours. 1 Haematological toxicity is no longer doselimiting. Instead, toxic effects to other organs, especially the gastro-intestinal tract (mucositis), prevent further dose The intensive cytotoxic treatment given in connection with bone marrow transplantations induces severe escalation. Clinically, mucositis can be categorised into oral toxicity which is characterized by mouth soreness and injury to the gut consistent with an increase in intestinal permeability. Currently, extent of the gut injury is which may lead to inability to eat and drink, and non-oral (gastro-intestinal) toxicity, manifesting with diarrhoea and assessed by inspecting the mouth and recording symptoms deriving from the gastro-intestinal tract. The aims abdominal pain, and which reflects diffuse intestinal injury. Gastro-intestinal permeability increases 2 may permit the of this study were to evaluate whether changes in permeability correlate with clinical assessment of gut passage of viable bacteria through the intestinal wall (bacterial translocation). 3 Various attempts have been made toxicity, according to the WHO criteria, and also to examine the duration of intestinal permeability after to circumvent mucositis, without convincing success. [4] [5] [6][7][8][9][10][11][12][13] In these trials, mostly focused on oral toxicity, the extent of high-dose chemotherapy. In 18 consecutive patients undergoing bone marrow transplantation, gastrogut damage has been evaluated clinically according to the WHO criteria. 14 Currently, no objective method is routinely intestinal permeability was assessed by a 51 Cr-EDTA absorption test before the start of cytotoxic treatment, used in clinical trials, as a complement to clinical evaluation, for the assessment of gastro-intestinal toxicity due and 4, 7, 10 and 14 days after stem-cell infusion. In another seven patients, permeability was assessed 2 days to chemotherapy and radiation. However, there are several reliable methods for non-invasive assessment of gastroafter the start of cytotoxic treatment, and 1, 7 and 14 days after stem cell infusion. During the same period, intestinal permeability in vivo, an accepted parameter for gut damage, 15 and the need for such a method has been oral-and non-oral clinical toxicity according to the WHO criteria were recorded. Permeability increased emphasized by others previously.
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The aims of this work were to evaluate whether changes significantly 2 days after the start of cytotoxic treatment (P Ͻ 0.05), on day 1 (P Ͻ 0.05), on day 4 (P Ͻ 0.0005), in permeability correlate with the clinical assessment of gut toxicity, according to the WHO criteria and to assess the on day 7 (P Ͻ 0.0005) and on day 10 (P Ͻ 0.005) after stem cell infusion, compared with pre-treatment perduration of the changes in intestinal permeability in the early post-transplant period. meability. Despite significant barrier dysfunction, clinical toxicity was very moderate in the early transplantation course. Gastro-intestinal, but not oral clinical Materials and methods toxicity requiring therapy, was consistent with a significant increase in permeability compared with no Patients clinical toxicity or toxicity not requiring therapy. Similarly, cumulative gastro-intestinal, but not oral toxicity Nineteen consecutive patients undergoing bone marrow transplantation at the Division of Haematology, Sahlgren's correlated positively with the increase in permeability. The permeability test was unable to predict the severity University Hospital, Gothenburg, Sweden were included. One patient was unable to participate because of nausea of the clinical gastro-intestinal toxicity. Keywords: bone marrow transplantation; gastro-intestiand vomiting, and was excluded. Another seven patients were included with the aim of investigating early changes nal toxicity; intestinal permeability; mucositis; Cr-EDTA in permeability (very soon after the start of the cytotoxic treatment). All patients studied are described in Table 1 . At the time of inclusion, none of the patients had a history of Bone marrow transplantation has improved prognosis for prior gastro-intestinal disease or symptoms from the gastropatients with haematological malignancies and with some intestinal tract. The patients had received no cytotoxic treatment for a mean of 36. Methods definition recorded as grade 3 or 4 according to the WHO criteria ( Table 2 ). Gastro-intestinal permeability was assessed by 51 Cr-EDTA All patients received prophylactic antibiotics absorption. 16 The test solution consisted of 4 MBq of 51 Cr-(ciprofloxacin, aciclovir, fluconazole) throughout the study labelled edetic acid ( 51 Cr-EDTA, specific activity 1-period and anti-emetic therapy (ondansetron) during con-2 mCi/mg chromium, Amersham International, UK), in ditioning therapy. 50 ml of water. At 08.00 after an overnight fast, the subjects emptied their bladders and then drank the test solution. Thereafter, they fasted for 1 h, after which normal food and Statistics fluid intake, except for alcohol, 17 was permitted. Urine was Data are expressed as means ± s.d. The Mann-Whitney U collected for the next 24 h. Three millilitres of the 24-h test was used for significance calculations of differences volume were counted for 5 min in a gamma-counter between the baseline 24-h urinary excretion and post-BMT (Selektronik, Hørsholm, Denmark). The 24-h urinary 24-h excretion. A P value Ͻ0.05 was considered statistiexcretion of the 51 Cr-EDTA was expressed as a percentage cally significant. Correlations between groups were tested of the dose given orally.
by linear correlation. In 18 patients, permeability was assessed before the start of cytotoxic treatment and 4, 7, 10 and 14 days after stem cell infusion. In another seven patients, permeability was Results assessed 2 days after the start of cytotoxic treatment and on day 1, day 7 and on day 14 after stem cell infusion.
During the same period, gastro-intestinal symptoms were Permeability (the mean percentage 24-h urinary excretion), increased significantly 2 days after the start of the cytotoxic recorded by a nurse and oral inspections were made by a dentist, both unaware of the permeability data. On the basis treatment (P Ͻ 0.05), on day 1 (P Ͻ 0.05), on day 4 (P Ͻ 0.0005), on day 7 (P Ͻ 0.0005), and on day 10 of these data, clinical oral and non-oral toxicity according to the WHO criteria were estimated. In the current study, (P Ͻ 0.005) after stem cell infusion, compared with the pre-treatment permeability. the term 'gastro-intestinal toxicity' (non-oral) refers to nausea/vomiting and diarrhoea taken together, and 'oral Two days after the start of conditioning treatment (n = 7), six patients showed no signs of either oral or gastro-intestitoxicity' refers only to toxicity from the oral cavity and throat. Toxicity requiring therapy (in addition to prophylacnal toxicity (grade 0), and on day 1 after stem cell infusion (n = 6) one patient developed symptoms from the gastrotic ondansetron during the conditioning therapy) is by In this study, the term 'non-oral toxicity' refers to nausea/vomiting and diarrhoea taken together. intestinal tract requiring therapy (grade 3), but no patient In order to evaluate cumulative clinical toxicity during the entire transplantation course, the total gastro-intestinal required therapy for oral toxicity.
Gastro-intestinal and oral toxicity seemed to peak on day WHO score in the 14 day post-transplant period (the sum of the grades of clinical toxicity on day 4, day 7, day 10 7 after stem cell infusion. By this time, four patients (20%) had very severe toxicity (grade 4) from the gastro-intestinal and day 14) was calculated for each individual (n = 18). It was found that this index of cumulative clinical toxicity tract and nine patients (45%) showed oral toxicity requiring therapy (grades 3 and 4) ( Table 3) . correlated positively with the mean individual relative change in permeability on the different measurement days. When investigating whether there was any correlation between clinical assessment of intestinal toxicity and No similar correlation was observed between oral clinical toxicity and permeability ( Figure 1 , data not shown for oral changes in permeability, it was found that gastro-intestinal toxicity requiring therapy (grades 3 and 4) was consistent toxicity). When making comparisons between clinical toxicity and permeability, clinical data were excluded if the with a significant increase in the 51 Cr-EDTA resorption compared with no clinical toxicity or toxicity not requiring corresponding permeability data were missing. The permeability test was unable to predict severity of therapy (grades 0, 1 and 2). On the other hand, there was no significant difference in the 51 Cr-EDTA resorption between the clinical gastro-intestinal toxicity and no other factor such as age, sex, diagnosis, days with fever or conditioning patients with oral toxicity requiring therapy (grades 3 and 4) or not (grades 0, 1 and 2; Table 4 ). treatment seemed to predict for the degree of clinical toxicity or high levels of 51 Cr-EDTA excretion. test. Among our patients, the test showed a two-to threefold increase in gastro-intestinal permeability after cytotoxic treatment, which parallels the increase in permeability for patients with exacerbation of inflammatory bowel disease, compared with that seen with inactive disease.
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A positive correlation between increase in permeability and cumulative gastro-intestinal toxicity was identified, but we were unable to demonstrate an analogous correlation regarding cumulative oral toxicity and permeability. Likewise, gastro-intestinal but not oral toxicity requiring therapy, was accompanied with a significant increase in permeability compared to toxicity not requiring therapy. These findings only emphasize the fact that symptoms from the oral cavity tell us very little about conditions occurring in the gastro-intestinal tract. Therefore, oral inspection cannot The main finding in this study was the demonstration of day post-transplant period and the mean relative increase in permeability a subclinical gastro-intestinal injury very soon after the start for each patient. r = 0.63, P = 0.0048, n = 18 (linear regression).
of cytotoxic treatment, which could only be demonstrated by revealing disruption of the intestinal barrier. Despite significant barrier dysfunction 2 days after the start of the conPermeability data were obtained on all measurement days in 13 patients, on four occasions in seven patients, on ditioning therapy, six patients out of seven, showed no signs of clinical gastro-intestinal toxicity, and none of the three occasions in four patients and on two occasions in one patient. In 11 cases, missed values were due to discharge of patients showed any signs of oral toxicity at this time. However, later on during the transplantation course, clinical toxthe patient before day 14 and because of technical problems (usually inadvertent loss of urine sample), in four cases icity seemed to catch up with the intestinal barrier dysfunction and it comes as no surprise that there is a significant because of vomiting (one male and three females) and in three cases because of contamination of the urine collection increase in permeability 4-7 days after stem cell infusion, which means about 2 weeks after the start of the cytotoxic by diarrhoea (all females). Baseline permeability data were obtained in all patients. No side-effects from the test soltreatment. By this time, histological evidence for gut abnormalities may already be present, 20 and therefore, an ution were recorded.
Seventeen patients received total parenteral nutrition increase in permeability may be anticipated. However, it is of greater interest for the formulation of a hypothesis (TPN) at a mean time of 9.1 ± 4.6 days (range 1-19). There was no correlation between duration of TPN treatment and concerning the pathophysiology of intestinal injury induced by chemotherapy and radiation, if it is possible to demonincrease in permeability.
strate disruption of the intestinal barrier to precede morphological changes. The early increase in permeability may be one of the initiating factors responsible for the development Discussion of intestinal injury after cytotoxic treatment. Similarly, increased intestinal permeability is involved in the early This study investigated the duration of intestinal permeability following intensive chemotherapy prior to bone pathophysiology of gut damage induced by non-steroidal anti-inflammatory drugs (NSAID enteropathy), which is marrow transplantation, and whether changes in permeability correlated with clinical assessment of intestinal characterised by a primary disruption of the intestinal barrier with secondary inflammatory changes, brought about and oral toxicity.
Gastro-intestinal permeability is an accepted parameter an imbalance between aggressive luminal factors and mucosal defence. 15 Increased permeability is, in this case, for evaluating gut damage 15 and it is known from former studies that there is a disruption of the intestinal barrier evident before histological changes develop. 21 If such an early increase in permeability is of importance for subwith bone marrow transplantation. 2, 11, 18 The need for an objective method for assessing gut damsequent morphological injury, intervention may be focused upon maintaining mucosal integrity, for instance by means age induced by cytotoxic treatment was emphasized as early as 1984 by Selby and coworkers. 2 However, no such of enteral nutrition or immunoabsorption of intestinal components. 22 It may therefore be of importance to evalumethod has been routinely used in trials against gastrointestinal toxicity induced by chemotherapy and radiation, ate permeability very soon after the start of the cytotoxic treatment, and our results which indicate an increase in perand we failed to find any publication evaluating duration of changes in permeability and how clinical symptoms meability 2 days after the start of cytotoxic treatment seem of interest. However, whether there is a similar pathophysicorrelated with intestinal barrier dysfunction.
It was confirmed that the 51 Cr-EDTA solution, which is ology for gut damage induced by chemotherapeutic agents as is the case for NSAID enteropathy remains to be both tasteless and odourless in contrast to different sugar probes, is very well tolerated by patients receiving chemoascertained.
Increased gastro-intestinal permeability may also play a therapy and only one patient was unable to complete the an animal model previously. Symptoms from the gastro-intestinal tract, but not from the
